Therapeutic
Areas
Therapeutic Areas
Hemato-Oncology
In collaboration with our partners, we continue to develop a full portfolio of generics and innovative molecules in the area of Hematology and Oncology. We have a diverse product list ranging from generic chemical drugs and peptides to more advanced biopharmaceutical products, specifically engineered and processed using bacterial cell lines and/or mammalian cell cultures. Additionally, our portfolio includes pegylated (polyethylene glycol PEG) and Liposomal therapeutic proteins that can help “mask” the agent from the host’s immune system thereby reducing immunogenicity and increasing the half –life of the drug. PEG and Liposomal drugs have demonstrated increased efficacy and safety with fewer adverse side effects.
Our products included:
-
Monoclonal antibodies
-
Recombinant drugs
-
Colony-stimulating Factors
-
Pegylated Proteins
-
Liposomal therapies
-
Albumin-bound nanoparticles
-
Nucleic acid synthesis inhibitor
-
Anti-emetics
-
Tyrosine kinase inhibitors
-
Cytotoxic drugs
Nephrology
XETLEY is a company dedicated to improving the quality of life and resolving complications of patients receiving dialysis or in chronic renal failure. Our products are focused on treating different conditions that frequently occur in patients with kidney function impairment. Our objectives are aimed at improving the chronic symptoms of decreased renal function and optimally manage bone-mineral metabolism and tissue calcifications in this population. Our company is also involved in providing therapies that ameliorate resulting calciphylaxis and diabetic ulcers from long term renal insufficiency and tissue hypoxia.
Our products included:
-
Vitamin D analogs
-
Iron Supplements
-
Erythropoiesis-stimulating agents
-
BFGF (fibroblast growth factor)
-
Phosphate Binders
-
Calcimimetics
Inmunology
The immune system is a highly regulated and balanced system and when disturbed, disease can result. In autoimmune diseases the immune system attacks the body it is meant to protect, leading to systemic inflammation from the marked increase of immune mediators and cytokines. Our commitment to helping patients extends to therapies for the management of autoimmune conditions such as, rheumatoid and psoriatic arthritis, systemic lupus, crohn’s disease, type I diabetes mellitus, inflammatory bowel syndrome, ankylosing spondylitis, psoriasis and multiple sclerosis.
Our products included:
-
TNF inhibitors
-
Immunomodulators
-
Human immunoglobulin
-
Tetanus immunoglobulin
-
Immunosuppressors
-
DMARDs
Infectious Diseases
Our focus in this field has been on the diagnosis and treatment of complex fungal, bacterial, and viral infections. Our therapies are centered on the management of nosocomial and community-acquired infections, management of patients with HIV/AIDS and other forms of Immunodeficiency, Hospitalized patients with severe fungal ailments, afflictions by the herpes virus and cytomegalovirus, and most recently the SARS-CoV2 Coronavirus responsible for the current pandemic. Regarding SARS-CoV2, Xetley is actively involved in the procurement of personal protective equipment (PPE), therapeutics, viral detection tests, neutralizing antibody assays, Ultra-low and Deep freezers and decontaminations products and devices. We are at the forefront in helping provide solutions that can help mitigate the catastrophic consequences suffered during this out-of-control COVID 19 Pandemic.
Our products included:
-
Liposomal Amphotericin
-
Deoxy-guanosine analogues
-
HIV fusion inhibitors
-
Echinocandins
-
Protein-synthesis inhibitors
-
NRTI / NtRTI
Rare Disease
Rare diseases are those that have a low prevalence in the population, specifically when they affect less than 5 of every 10,000 inhabitants. According to WHO, approximately 7% of the world population is affected by the more than 7,000 rare diseases that exist so far. For patients who suffer from these unique conditions, their family members and for the health team in charge of their diagnosis and care, it is challenging to find disease information, diagnostic methods, adequate treatment facilities and even therapeutic alternatives that can improve their quality of life. Xetley, is committed to bringing treatment alternatives and education to patients and family members affected by lysosomal storage diseases, idiopathic pulmonary fibrosis, hereditary and acquired bleeding disorders and certain leukemias. Fulfilling patient’s needs is our number one priority!
Our products included:
-
Glucocerebrosidase enzyme replacement
-
Iduronate-2-sulfatase enzyme replacement
-
PEG L-Asparaginase
-
Erwinia L-Asparaginase
-
Recombinant Factor VIII
-
Antifibrotics
Our Team
Convallis ullamcorper aliquet ultrices orci cum vestibulum lobortis erat.
Changing lives one patient at time!